5-MeO-DMT (toad venom)

psilodex.org/m/5-meo-dmt · data v2026.10.02

Clinical contraindication: Relative; Substantial clinical concern; the literature treats it as a reason for caution or deferral.
Best available evidence: Case reports; Also: mechanism only.
Half-life: Not recorded

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: 5-meo-dmt · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

CR · Th

Potent, fast-acting tryptamine acting at 5-HT1A and 5-HT2A receptors. MAO-A clears it, so harmala or other MAOI combinations sharply raise exposure and can cause serotonin toxicity; a death followed 5-MeO-DMT in a harmala-containing brew. No psilocybin-combination data.

Human data with psilocybin: Case reports or surveys only

Evidence types on this record

CRCase reports or online surveys

ThMechanism only (theoretical)

02 Pharmacology relevant to psilocybin

1 listed · counted on reports

Serotonergic: Increases serotonin activity, for example by blocking its reuptake or releasing it. Psilocybin acts on serotonin receptors, so effects can add together. With antidepressant use, the psilocybin response can be weaker. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-02

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

Shen HW, Jiang XL, Winter JC, Yu AM. Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Curr Drug Metab 2010;11(8):659–666. — nonselective 5-HT agonist; MAO-A deamination; harmaline raises exposure; serotonin toxicity possible
Halberstadt AL. Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine. Pharmacol Biochem Behav 2016;143:1–10. — 5-HT1A-mediated effects; MAOI pretreatment raised plasma and brain 5-MeO-DMT (rats)
Sklerov J, Levine B, Moore KA, King T, Fowler D. A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. J Anal Toxicol 2005;29(8):838–841. — fatal case: 5-MeO-DMT 1.88 mg/L with harmine, harmaline, tetrahydroharmine in an ayahuasca-type preparation
Reckweg J, Mason NL, van Leeuwen C, et al. A phase 1, dose-ranging study to assess safety and psychoactive effects of a vaporized 5-MeO-DMT formulation (GH001) in healthy volunteers. Front Pharmacol 2021;12:760671. — ultra-rapid onset, short duration; phase 1 inhaled dosing in healthy volunteers

Record history

v2026.10.02First published.
2026-10-02Last reviewed against its sources.

Report an error in this record →